PharmaEngineROCO:4162 -2.71%79 Interest Coverage is 1,565.34 as of Dec. 2025, which is 54% below its 10-year median of 3,366.53. GuruFocus rates ROCO:4162 with a GF Score™ of 79/100 and a GF Value™ of NT$115.08 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 377 Biotechnology companies, PharmaEngine ranks better than 62.6% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. PharmaEngine's
Operating Income
for the
three
months ended in Dec. 2025 was NT$119.0 Mil. PharmaEngine's Interest Expense for the
three
months ended in Dec. 2025 was NT$-0.1 Mil.
PharmaEngine's interest coverage for the quarter that ended in Dec. 2025 was 1,565.34.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. PharmaEngine Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for PharmaEngine's Interest Coverage or its related term are showing as below:
ROCO:4162'
s Interest Coverage Range Over the Past 10 Years
Min: 291.16 Med: 3366.53 Max: 11343.46
Current: 3061.02
ROCO:4162's Interest Coverage is ranked better than 62.6% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs ROCO:4162: 3061.02
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
PharmaEngine Interest Coverage Related Terms
PharmaEngine Interest Coverage Historical Data
* Premium members only.
The historical data trend for PharmaEngine's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ROCO:4162 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, PharmaEngine's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaEngine Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaEngine's Interest Coverage distribution charts can be found below:
* The bar in red indicates where PharmaEngine's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaEngine (ROCO:4162) has a Interest Coverage of 1,565.34 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PharmaEngine and its competitors. This is 54% below median its historical median of 3,366.53. Over the past decade, PharmaEngine's Interest Coverage has ranged from 291.16 to 11,343.46. According to the industry distribution chart, PharmaEngine ranks #141 out of 377 companies in the Biotechnology industry, placing it in the top 37.4%.
Is PharmaEngine's Interest Coverage too high?
PharmaEngine's current Interest Coverage of 1,565.34 is 54% below median its 10-year median of 3,366.53. Over the past 10 years, this metric has ranged from a low of 291.16 to a high of 11,343.46. The Biotechnology industry median Interest Coverage is 106.07. PharmaEngine's value of 1,565.34 is 1375.8% above this industry median. Based on the distribution chart, PharmaEngine ranks #141 out of 377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PharmaEngine has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PharmaEngine ranks #141 out of 377 companies for Interest Coverage. This puts PharmaEngine in the upper half of its industry. The industry median Interest Coverage is 106.07. PharmaEngine's value of 1,565.34 is 1375.8% above this benchmark. Historically, PharmaEngine's own Interest Coverage has ranged from 291.16 to 11,343.46 over the past decade. While the company's 10-year median is 3,366.53 vs. the industry median of 106.07, PharmaEngine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaEngine's current Interest Coverage of 1,565.34 is 1375.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PharmaEngine and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaEngine's current Interest Coverage is 1,565.34, which is 54% below median its own 10-year median of 3,366.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$115.08, compared to a current price of NT$61.00 — trading 47% below its estimated fair value. The current Interest Coverage is 1,565.34, which is 54% below median its 10-year median of 3,366.53 and 1375.8% above the Biotechnology industry median of 106.07. PharmaEngine's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current Interest Coverage is 1,565.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaEngine (ROCO:4162) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued.
The current stock price of NT$61.00 is trading 47% below its estimated GF Value™ of NT$115.08.
GuruFocus considers PharmaEngine to be Significantly Undervalued.
Key valuation signals for ROCO:4162:
Interest Coverage: 1,565.34 (54% below median its 10-year median of 3,366.53)
GF Value™: NT$115.08 vs. price of NT$61.00 (47% below fair value)
Industry Position: 1375.8% above the Biotechnology median (#141 of 377)
No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
79GF Score
Get the complete analysis for ROCO:4162
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4162 has been successfully added to your 
